These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 4462871)
1. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man]. Castaigne P; Rondot P; Taberlet A; Baumann N Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871 [No Abstract] [Full Text] [Related]
2. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor]. Rabadeau Dumas JL; Rondot P; Cardon P Therapie; 1977; 32(2):161-72. PubMed ID: 898124 [No Abstract] [Full Text] [Related]
3. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease]. Rondot P Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964 [No Abstract] [Full Text] [Related]
4. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549 [No Abstract] [Full Text] [Related]
5. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)]. Puca FM; Megna GF; Masi G; Specchio LM Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268 [No Abstract] [Full Text] [Related]
6. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336 [No Abstract] [Full Text] [Related]
7. [Variations of the therapeutic action (on-off phenomenon) in patients with Parkin]. Carolei A; Casacchi M; Fazio C Clin Ter; 1977 Jan; 80(2):181-9. PubMed ID: 844268 [No Abstract] [Full Text] [Related]
8. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment. Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895 [TBL] [Abstract][Full Text] [Related]
9. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602). Chouza C; Romero S; Gomensoro JB Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960 [No Abstract] [Full Text] [Related]
10. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]
11. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study]. Boismare F; Boquet J; Lefrançois J; Le Poncin M Agressologie; 1977; 18(5):285-6. PubMed ID: 602991 [No Abstract] [Full Text] [Related]
12. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome]. Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252 [No Abstract] [Full Text] [Related]
13. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]. Mizuno Y; Yoshida M; Obayashi T; Ueki A Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921 [No Abstract] [Full Text] [Related]
14. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism]. Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014 [No Abstract] [Full Text] [Related]
15. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]. Dessibourg CA; Gachoud JP Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341 [TBL] [Abstract][Full Text] [Related]
16. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination]. Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929 [No Abstract] [Full Text] [Related]
17. [The L-dopa test in Parkinson's disease]. Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar]. Kamenetskiĭ VK Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958 [No Abstract] [Full Text] [Related]
19. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602. Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646 [No Abstract] [Full Text] [Related]
20. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669 [No Abstract] [Full Text] [Related] [Next] [New Search]